Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Recurrence 4 Ovarian Neoplasms 4 Glioblastoma 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Radiation Pneumonitis 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Fallopian Tube Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Pancreatic Neoplasms 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasms 1 Mesothelioma, Malignant 1 Melanoma, Cutaneous Malignant 1 Lymphangioleiomyomatosis 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Esophagogastric Adenocarcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

nintedanib 1 Vitamin D 1 Surveys and Questionnaires 1 Paclitaxel 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Cholecalciferol 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Melanoma, Cutaneous Malignant × nintedanib × Clear all

NCT02308553 2020-10-14

NIPAWILMA

University Hospital, Essen

Phase 1/2 Completed

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡